This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Segal, R Articles by Mozes, E Search for Related Content PubMed PubMed Citation Articles by Segal, R Articles by Mozes, E Social Bookmarking                   What's this?

Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF monoclonal antibody and by pentoxiphylline

Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel; Shmuel Harofeh Geriatric Medical Center, Beer Yacov, Israel

M Dayan

H Zinger

E Mozes

Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel

We have previously shown that the clinical manifestations of experimental systemic lupus erythematosus (SLE) correlate with an early increased secretion of TNF and IL-1. In the present study, we examined the efficacy of two therapeutic modalities which lower TNF production or activity, on the clinical manifestations of the disease. Experimental SLE was induced in naive C3H.SW mice by injection of the human anti-DNA monoclonal antibody (mAb) bearing the common idiotype, 16/6 Id. Two weeks after booster injections, treatment with either an anti-TNF mAb, or pentoxiphylline (PTX) was started, for a period of 6 weeks. Production of TNF (by splenocytes) and IL-1 (by peritoneal macrophages) was determined 3 and 7 months after disease induction. The experimental mice were also followed for disease manifestations. Both treatment protocols, with anti-TNF mAb and with PTX, reduced the production of the two pro-inflammatory cytokines, TNF and IL-1, in mice with experimental SLE. Anti-DNA antibodies were significantly lower in the mice treated with either protocol. In addition, a significantly lower rate of leukopenia, proteinuria and immune complex deposition was observed in treated mice. Abrogation of TNF and IL-1 production in the early stages of experimental SLE by an anti-TNF mAb or by PTX improves the clinical status of mice affiicted with this autoimmune disease.

Key Words: anti TNF • experimental SLE

Lupus, Vol. 10, No. 1, 23-31 (2001)
DOI: 10.1191/096120301675275538


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. F. Navarro-Gonzalez and C. Mora-Fernandez The Role of Inflammatory Cytokines in Diabetic Nephropathy J. Am. Soc. Nephrol., March 1, 2008; 19(3): 433 - 442. [Abstract] [Full Text] [PDF]

				J. F. Navarro, C. Mora, M. Muros, and J. Garcia Additive Antiproteinuric Effect of Pentoxifylline in Patients with Type 2 Diabetes under Angiotensin II Receptor Blockade: A Short-Term, Randomized, Controlled Trial J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2119 - 2126. [Abstract] [Full Text] [PDF]

				M Aringer and J S Smolen Cytokine expression in lupus kidneys Lupus, January 1, 2005; 14(1): 13 - 18. [Abstract] [PDF]

				M Aringer and J S Smolen Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention Lupus, May 1, 2004; 13(5): 344 - 347. [Abstract] [PDF]

				Y.-M. Chen, Y.-Y. Ng, S.-L. Lin, W.-C. Chiang, H. Y. Lan, and T.-J. Tsai Pentoxifylline suppresses renal tumour necrosis factor-{alpha} and ameliorates experimental crescentic glomerulonephritis in rats Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1106 - 1115. [Abstract] [Full Text] [PDF]

				M Blank, I Krause, G Wildbaum, N Karin, and Y Shoenfeld TNF {alpha}DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome Lupus, July 1, 2003; 12(7): 546 - 549. [Abstract] [PDF]

				M Aringer, E Feierl, G Steiner, G H Stummvoll, E Hofler, C W Steiner, I Radda, J S Smolen, and W B Graninger Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death Lupus, February 1, 2002; 11(2): 102 - 108. [Abstract] [PDF]